

CarThera appoints Pascal E. R. Girin as chairman of board of directors

June 28, 2019 | News

Girin brings wealth of experience in medical device and life sciences industries to support CarThera's future growth



CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces the appointment of Pascal E. R. Girin as chairman of its board of directors.

Girin has decades of business expertise in the life sciences and medical devices markets, most recently as CEO of Balt, a leader in the treatment of neurovascular diseases. Prior to this, he held numerous C-level positions at leading medical companies, including Wright Medical, Keystone Dental (a Warburg Pincus company), EV3, Baxter and Ohmeda, among others.

Girin has considerable experience as a member of six medical devices company boards, having served at MRI Interventions, Biom'Up, Silk Road Medical, Keystone Dental, Tornier and Mauna Kea Technologies. He has a degree in engineering from the École Nationale Supérieure des Mines.

As chairman of CarThera's board of directors, Girin will bring invaluable insight to the company's business strategy and future development.

Frederic Sottolini, CEO of CarThera said, "We are thrilled to welcome Pascal, a well-versed business expert, to head up our board of directors. We have far-reaching plans for our SonoCloud-9 device in the treatment of glioblastoma and other brain conditions, including neurodegenerative diseases. Pascal is a great addition to our leadership team for turning these plans into reality."

"I'm excited to join CarThera at such a crucial time for the company. I believe that my experience in medical devices worldwide, and more specifically in the United States, will bring tremendous support in the development of clinical programs and expansion of the business", Pascal E.R. Girin

CarThera recently published complete results of its Phase I/IIa glioblastoma study on the ultrasound-induced blood-brain barrier (BBB) opening using its SonoCloud-1 implant, aimed at improving the efficiency of carboplatin chemotherapy.

The company is now recruiting recurrent GBM patients for its new clinical trial with the SonoCloud-9 implantable ultrasound device, which is designed to cover a volume nine times larger than the previous generation device. This advanced device will cover the tumor and surrounding infiltrative areas.

SonoCloud® is an innovative medical device developed by CarThera. It emits ultrasound to temporarily increase the permeability of the blood vessels in the brain.